Senseonics to Host Virtual KOL Event on Eversense 365: FDA Clearance and Commercialization Plans for the World's First One-Year CGM System
16 Octobre 2024 - 10:30PM
Senseonics Holdings, Inc. (NYSE American: SENS), a medical
technology company focused on the development and manufacturing of
long-term, implantable continuous glucose monitoring (CGM) systems
for people with diabetes, today announced it will host a virtual
KOL event on Friday, October 25, 2024 at 11:00am ET. To register,
click here.
The event will feature David T. Ahn, MD, and
endocrinologist and Chief of Diabetes Services at Hoag Medical
Group, and Jeff Ciaramita, MD, President, Speciality
Service Lines at Mercy, who will join company management to
discuss the next-generation Eversense® 365 Continuous Glucose
Monitoring (CGM) system, which was recently cleared by the U.S.
Food and Drug Administration (FDA) for people with Type 1 and Type
2 diabetes aged 18 years and older.
The event will highlight Eversense 365 in
clinical practice and include an overview of Senseonics' commercial
collaboration with the St. Louis-based healthcare system Mercy.
Eversense 365, the world’s first one-year CGM
system, represents a significant breakthrough in diabetes
technology and management that is highly differentiated from
short-term CGMs.
A live question and answer session will follow
the formal presentations.
Registration details can be found
here. For those who are unable to attend live, a replay
will be available by clicking here.
About Eversense
The Eversense® Continuous Glucose Monitoring
(CGM) Systems are indicated for continually measuring glucose
levels for up to 365 days for Eversense® 365 and 180 days for
Eversense® E3 in persons with diabetes age 18 and older. The
systems are indicated for use to replace fingerstick blood glucose
(BG) measurements for diabetes treatment decisions. Fingerstick BG
measurements are still required for calibration primarily one time
per week after day 14 for Eversense® 365 and one time per day after
day 21 for Eversense® E3, and when symptoms do not match CGM
information or when taking medications of the tetracycline class.
The sensor insertion and removal procedures are performed by a
health care provider. The Eversense CGM Systems are prescription
devices; patients should talk to their health care provider to
learn more. For important safety information, see
www.eversensediabetes.com/safety-info/.
About Senseonics
Senseonics Holdings, Inc. ("Senseonics") is a
medical technology company focused on the development and
manufacturing of glucose monitoring products designed to transform
lives in the global diabetes community with differentiated,
long-term implantable glucose management technology. Senseonics'
CGM system Eversense® 365 includes a small sensor inserted
completely under the skin that communicates with a smart
transmitter worn over the sensor. The glucose data are
automatically sent every 5 minutes to a mobile app on the user's
smartphone.
About Mercy
Mercy, one of the 20
largest U.S. health systems and named the top large
system in the U.S. for excellent patient experience by
NRC Health, serves millions annually with nationally recognized
care and one of the nation’s largest and highest performing
Accountable Care Organizations in quality and cost. Mercy is a
highly integrated, multi-state health care system including more
than 50 acute care and specialty (heart, children’s, orthopedic and
rehab) hospitals, convenient and urgent care locations, imaging
centers and pharmacies. Mercy has over 900 physician practice
locations and outpatient facilities, more than 4,500 physicians and
advanced practitioners and 50,000 co-workers serving patients and
families
across Arkansas, Kansas, Missouri and Oklahoma.
Mercy also has clinics, outpatient services and outreach ministries
in Arkansas, Louisiana, Mississippi and Texas.
In fiscal year 2023 alone, Mercy provided more than half a billion
dollars of free care and other community benefits, including
traditional charity care and unreimbursed Medicaid.
Senseonics Investor Contact
Jeremy FefferLifeSci
Advisorsinvestors@senseonics.com
Mercy Communications
Contact
Bethany Pope 314-251-4472 Mercy Media
RelationsBethany.Pope@Mercy.Net
Senseonics (AMEX:SENS)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Senseonics (AMEX:SENS)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024